Minocycline and N‐methyl‐4‐isoleucine cyclosporin (NIM811) mitigate storage/reperfusion injury after rat liver transplantation through suppression of the mitochondrial permeability transition

Tom P. Theruvath, Zhi Zhong, Peter Pediaditakis, Venkat K. Ramshesh, Robert T. Currin, Andrey Tikunov, Ekhson Holmuhamedov, John J. Lemasters – 26 December 2007 – Graft failure after liver transplantation may involve mitochondrial dysfunction. We examined whether prevention of mitochondrial injury would improve graft function. Orthotopic rat liver transplantation was performed after 18 hours' cold storage in University of Wisconsin solution and treatment with vehicle, minocycline, tetracycline, or N‐methyl‐4‐isoleucine cyclosporin (NIM811) of explants and recipients.

Matrix metalloproteinase inhibition protects rat livers from prolonged cold ischemia–warm reperfusion injury

Virginie Defamie, Marina Laurens, Damiano Patrono, Laurent Devel, Antoine Brault, Marie‐Christine Saint‐Paul, Athanasios Yiotakis, Pascal Barbry, Jean Gugenheim, Dominique Crenesse, Vincent Dive, Pierre‐Michel Huet, Bernard Mari – 26 December 2007 – Matrix metalloproteinases (MMPs) have been implicated in the hepatic injury induced after cold ischemia–warm reperfusion (CI‐WR), by altering the extracellular matrix (ECM), but their precise role remains unknown.

Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?

Tito Livraghi, Franca Meloni, Michele Di Stasi, Emanuela Rolle, Luigi Solbiati, Carmine Tinelli, Sandro Rossi – 26 December 2007 – If liver transplantation is not feasible, partial resection is considered the treatment of choice for hepatocellular carcinoma (HCC) in patients with cirrhosis. However, in some centers the first‐line treatment for small, single, operable HCC is now radiofrequency ablation (RFA). In the current study, 218 patients with single HCC ≤ 2.0 cm (very early or T1 stage) underwent RFA.

Peroxisome proliferator‐activated receptor‐γ protects against hepatic ischemia/reperfusion injury in mice

Satoshi Kuboki, Thomas Shin, Nadine Huber, Thorsten Eismann, Elizabeth Galloway, Rebecca Schuster, John Blanchard, Basilia Zingarelli, Alex B. Lentsch – 26 December 2007 – The function of peroxisome proliferator‐activated receptor‐γ (PPARγ) in hepatic inflammation and injury is unclear. In this study, we sought to determine the role of PPARγ in hepatic ischemia/reperfusion injury in mice. Male mice were subjected to 90 minutes of partial hepatic ischemia followed by up to 8 hours of reperfusion. PPARγ was found to be constitutively activated in hepatocytes but not in nonparenchymal cells.

Metalloproteinase‐9 deficiency protects against hepatic ischemia/reperfusion injury

Takashi Hamada, Constantino Fondevila, Ronald W. Busuttil, Ana J. Coito – 26 December 2007 – Leukocyte transmigration across endothelial and extracellular matrix protein barriers is dependent on adhesion and focal matrix degradation events. In the present study we investigated the role of metalloproteinase‐9 (MMP‐9/gelatinase B) in liver ischemia/reperfusion (I/R) injury using MMP‐9‐deficient (MMP‐9−/−) animals and mice treated with a specific anti‐MMP‐9 neutralizing antibody or with a broad gelatinase inhibitor for both MMP‐9 and metalloproteinase‐2 (MMP‐2/gelatinase A).

Tolerogenic maturation of liver sinusoidal endothelial cells promotes B7‐homolog 1‐dependent CD8+ T cell tolerance

Linda Diehl, Anna Schurich, Regina Grochtmann, Silke Hegenbarth, Lieping Chen, Percy A. Knolle – 26 December 2007 – Liver sinusoidal endothelial cells (LSEC) are unique organ‐resident antigen‐presenting cells capable of cross‐presentation and subsequent tolerization of naïve CD8+ T cells. We investigated the molecular mechanisms underlying this tolerance induction in naive CD8+ T cells.

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

Olav Dalgard, Kristian Bjøro, Helmer Ring‐Larsen, Einar Bjornsson, Mona Holberg‐Petersen, Eva Skovlund, Olle Reichard, Bjørn Myrvang, Bo Sundelöf, Ståle Ritland, Kjell Hellum, Aril Frydén, Jon Florholmen, Hans Verbaan, North‐C Group – 26 December 2007 – A recent nonrandomized pilot trial showed that hepatitis C virus (HCV) patients with genotype 2/3 and rapid virological response (RVR) had a 90% sustained virological response (SVR) rate after 14 weeks of treatment. We aimed to assess this concept in a randomized controlled trial.

CXCL10 regulates liver innate immune response against ischemia and reperfusion injury

Yuan Zhai, Xiu‐Da Shen, Feng Gao, Alice Zhao, Maria Cecilia Freitas, Charles Lassman, Andrew D. Luster, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski – 26 December 2007 – We have shown that activation of toll‐like receptor 4 (TLR4) and its interferon regulatory factor 3 (IRF3)‐dependent downstream signaling pathway are required for the development of liver ischemia/reperfusion injury (IRI). This study focused on the role of TLR4‐IRF3 activation pathway products, in particular, chemokine (C‐X‐C motif) ligand 10 (CXCL10).

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma

Alejandro Forner, Ramón Vilana, Carmen Ayuso, Lluís Bianchi, Manel Solé, Juan Ramón Ayuso, Loreto Boix, Margarita Sala, María Varela, Josep M Llovet, Concepció Brú, Jordi Bruix – 26 December 2007 – This study prospectively evaluates the accuracy of contrast‐enhanced ultrasound (CEUS) and dynamic magnetic resonance imaging (MRI) for the diagnosis of nodules 20 mm or smaller detected during ultrasound (US) surveillance.

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

Alessandra Mangia, Nicola Minerva, Donato Bacca, Raffaele Cozzolongo, Giovanni L. Ricci, Vito Carretta, Francesco Vinelli, Gaetano Scotto, Giuseppe Montalto, Mario Romano, Giuseppe Cristofaro, Leonardo Mottola, Fulvio Spirito, Angelo Andriulli – 26 December 2007 – It was hypothesized that in hepatitis C virus (HCV) genotype 1 patients, variable treatment duration individualized by first undetectable HCV RNA is as effective as standard 48‐week treatment.

Subscribe to